United Therapeutics Corporation (Nasdaq:UTHR) hit a new 52-week high Thursday as it changed hands at $69.67 compared with its previous 52-week high of $69.48. United is currently trading at $69.67 with 161,985 shares changing hands as of 12:17 p.m..
NEW YORK ( TheStreet) -- United Therapeutics Corporation (Nasdaq: UTHR) hit a new 52-week high Thursday as it traded at $69.67 compared with its previous 52-Week high of $69.48. United is changing hands at $69.67 with 161,985 shares traded as of 12:17 p.m. ET. Average volume has been 550,500 shares over the past 30 days. United has a market cap of $3.9 billion and is part of the health care sector and drugs industry. Shares are up 7.8% year to date as of the close of trading on Wednesday. United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening diseases in the United States and Internationally. The company has a P/E ratio of 37.6, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 21.5. TheStreet Ratings rates United as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full United Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.